OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx
June 22 2021 - 8:00AM
OPKO Health, Inc. (NASDAQ: OPK) today announced
the appointment of Katherine Stueland as President and Chief
Executive Officer of GeneDx, Inc., the global genomics subsidiary
of OPKO’s BioReference Laboratories. Ms. Stueland joins GeneDx from
Invitae Corporation (NYSE: NVTA), where she served most recently as
Chief Commercial Officer, establishing the corporate brand as
Invitae evolved from a private company to a public entity with a
market capitalization exceeding $6 billion.
“We’re thrilled to have Katherine lead the team
at GeneDx, which has served clinicians and patients for more than
two decades with novel and differentiated technologies for
diagnosing the most difficult human diseases,” said Jon R. Cohen,
MD, Executive Chairman of BioReference Laboratories. “With her
depth of experience, focus on patient-centric business strategies
and ability to lead and inspire, we look forward to a new era of
genomics with GeneDx at the forefront.”
Ms. Stueland’s career is rooted in bringing
transformational technologies to patients and crafting strategies
to enable broader access to diagnostics and therapeutics. She has
overseen multiple commercial organizations and corporate brand
transformations, and helped bring the first cancer immunotherapy to
market, enabling a new standard of care for patients.
“The global opportunity is clear regarding the
growing role of genomic information in providing better care to
patients. We can readily and rapidly provide critical information
to improve health outcomes, and GeneDx has been at the forefront of
these efforts for more than 20 years,” said Ms. Stueland, incoming
President and CEO of GeneDx. “I’m honored to be joining this
world-class team and couldn’t be more excited about what’s possible
by bringing the GeneDx technologies to broader patient
populations.”
With more than two decades in the healthcare
industry, Ms. Stueland previously held roles at Dendreon
Corporation and TAP Pharmaceuticals (a joint venture of Takeda and
Abbott), and consulted for biotech and pharmaceutical
companies.
About GeneDx
GeneDx, Inc. is a global leader in genomics,
providing testing to patients and their families from more than 55
countries. Led by its world-renowned clinical genomics program,
GeneDx has an acknowledged expertise in rare and ultra-rare genetic
disorders, as well as one of the broadest menus of sequencing
services available among commercial laboratories. GeneDx offers a
suite of additional genetic testing services, including diagnostic
testing for hereditary cancers, cardiac, mitochondrial,
neurological disorders, prenatal diagnostics and targeted variant
testing. GeneDx is a subsidiary of BioReference Laboratories, Inc.,
a wholly owned subsidiary of OPKO Health, Inc. To learn more,
please visit www.genedx.com.
About OPKO Health
OPKO is a multinational biopharmaceutical and
diagnostics company that seeks to establish industry-leading
positions in large, rapidly growing markets by leveraging its
discovery, development, and commercialization expertise and novel
and proprietary technologies. For more information, visit
www.opko.com.
Cautionary Statement Regarding Forward
Looking Statements
This press release contains "forward-looking
statements," as that term is defined under the Private Securities
Litigation Reform Act of 1995 (PSLRA), which statements may be
identified by words such as "expects," "plans," "projects," "will,"
"may," "anticipates," "believes," "should," "intends," "estimates,"
and other words of similar meaning, including statements regarding
expected market reach, financial performance as well as other
non-historical statements about our expectations, beliefs or
intentions regarding our business, financial condition, or
strategies. Many factors could cause our actual activities or
results to differ materially from the activities and results
anticipated in forward-looking statements. These factors include
those described in our Annual Reports on Form 10-K filed and to be
filed with the Securities and Exchange Commission and under the
heading “Risk Factors” in our other filings with the Securities and
Exchange Commission. In addition, forward-looking statements may
also be adversely affected by general market factors, competitive
product development, product availability, federal and state
regulations and legislation, the regulatory process for new
products and indications, manufacturing issues that may arise,
patent positions and litigation, among other factors. The
forward-looking statements contained in this press release speak
only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements. We
intend that all forward-looking statements be subject to the
safe-harbor provisions of the PSLRA.
Contacts:
LHA Investor RelationsYvonne
Briggs, 310-691-7100ybriggs@lhai.com orBruce Voss, 310-691-7100
bvoss@lhai.com
Invitae (NYSE:NVTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Invitae (NYSE:NVTA)
Historical Stock Chart
From Sep 2023 to Sep 2024